Details for New Drug Application (NDA): 019614

✉ Email this page to a colleague

NDA 019614 describes VERELAN, which is a drug marketed by Azurity and is included in two NDAs. It is available from three suppliers. Additional details are available on the VERELAN profile page.

The generic ingredient in VERELAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for 019614

Tradename:	VERELAN
Applicant:	Azurity
Ingredient:	verapamil hydrochloride
Patents:	0

Pharmacology for NDA: 019614

Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

Medical Subject Heading (MeSH) Categories for 019614

Anti-Arrhythmia Agents
Calcium Channel Blockers
Vasodilator Agents

Suppliers and Packaging for NDA: 019614

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614	NDA	Teva Pharmaceuticals Inc	0591-2880	0591-2880-01	100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (0591-2880-01)
VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614	NDA	Teva Pharmaceuticals Inc	0591-2882	0591-2882-01	100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (0591-2882-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE, EXTENDED RELEASE;ORAL			Strength	120MG
Approval Date:	May 29, 1990	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE, EXTENDED RELEASE;ORAL			Strength	240MG
Approval Date:	May 29, 1990	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE, EXTENDED RELEASE;ORAL			Strength	180MG
Approval Date:	Jan 9, 1992	TE:	AB	RLD:	Yes

Expired US Patents for NDA 019614

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-004	May 10, 1996	⤷ Sign Up	⤷ Sign Up
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-001	May 29, 1990	⤷ Sign Up	⤷ Sign Up
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-002	May 29, 1990	⤷ Sign Up	⤷ Sign Up
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-003	Jan 9, 1992	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.